Kailera Therapeutics is entering what analysts describe as a 'catalyst-rich period' following its record-breaking $625 million initial public offering, according to a May 28 report. The company is advancing three obesity drug candidates that follow the clinical path established by Eli Lilly’s weight-loss products.
William Blair told investors, “We view Kailera’s broad GLP-1-based pipeline as largely de-risked through clinical and commercial validation from competitor programs, especially those from Eli Lilly.” Kailera’s lead candidate, ribupatide, acts as a dual agonist of the GLP-1 and GIP receptors—similar to Lilly's Zepbound. The biotech is also developing KAI-7535, an oral small-molecule GLP-1 pill, and KAI-4729, a triple-G agonist. These assets mirror the mechanisms of Lilly's Foundayo and investigational retatrutide.
Despite strong competition in the obesity market set by Lilly’s successes, William Blair said there remains opportunity for Kailera: “The company’s medicines could provide ‘options for patients with various weight-loss goals and across the full treatment journey.’”
Kailera launched in October 2024 with $400 million in starting capital and rights outside China to several weight-loss assets licensed from Jiangsu Hengrui. Before going public, it secured $600 million in series B funding in October 2025. With its recent IPO—the largest ever for a biotech firm—Kailera now trades on Nasdaq.
On May 28, Kailera announced initiation of a Phase 2b study evaluating higher doses of injectable ribupatide; data are expected next year. Ribupatide will also enter a broader Phase 3 program called KaiNETIC, with initial results anticipated in 2028. For KAI-7535, new data from a Phase 3 diabetes study conducted by Hengrui showed patients taking the drug experienced HbA1c reductions between 1.40% and 1.68% at week 32, compared to placebo recipients who saw only a 0.06% decrease.
Hengrui plans to release additional Phase 3 data for KAI-7535 targeting obesity later this year, while Kailera prepares an early-stage trial for KAI-4729 outside China with results expected next year—a program likely to be compared closely against Lilly's retatrutide, which recently demonstrated significant weight loss over an extended period.
